Novavax Inc (NVAX)
$37.38
1.99 (5.05%)
NVAX Stock Quote Delayed 30 Minutes
Don’t Bet on New Highs for Novavax Stock
Investors would do well to avoid repeating the mistake of expecting moonshots in NVAX stock. The business may do better, but the stock won't.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
2.78B
PE Ratio
-2.86
EPS
-13.06
Volume (Avg. Vol.)
3.15M
Day's Range
$37.34 - $39.75
52-Week Range
$34.88 - $277.80
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
What to Make of Novavax’s Adolescent Covid-19 Vaccine Move
Novavax stock's foray in the adolescent Covid-19 vaccine market could pay dividends but investors should tread with caution at this time as risk remains.
Novavax’s First Canadian Shipments Are Boosting NVAX Stock
Novavax delivered its first shipments to Canadian health authorities last week, and the news continues to help NVAX stock climb higher today.
Novavax Stock Is Alluringly Attractive at This Stage
Novavax is close to securing FDA approval for its Covid-19 vaccine yet NVAX stock is down since the end of January. What gives?
How to Approach Trading Downtrodden Novavax Today
There are obvious reasons to be bearish on NVAX stock's price chart, but a word to the wise would include the use of this type of put spread.
The Waiting Game Is Wearing Thin for Novavax Investors
If you’re not otherwise engaged with NVAX stock, it’s best to wait until the picture gets clearer on EUA approval.
Novavax’s Success Depends on the FDA’s Decision
While Novavax awaits the FDA approval, the frustration amongst investors is rising and a lot is on stake. Take a small position in NVAX stock.
Why Novavax Stock Is Due for a Comeback Soon
As Novavax has its Covid-19 vaccine authorized in multiple major world markets, NVAX stock is overdue for a re-rating on Wall Street.
Investors Should Not Lose Faith in Novavax
The valuation of NVAX stock is quite attractive while Novavax continues to make progress in many important areas.
Why Is Novavax (NVAX) Stock in the Spotlight Today?
Novavax is once again in the spotlight as China reports near-record numbers of Covid cases. What's going on with NVAX stock?
Novavax Revenue Guidance Does Little to Change Neutral Stance on the Stock
NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance.
Russia’s Aggression Could Put a Damper on Novavax Global Vax Deployment
The best chance for profits with NVAX stock is with the international market. But Russia's invasion of Ukraine could put Novavax's strategy at risk.
Novavax: The Frustration Is Real, And So Is the Sales Potential
All isn't well with NVAX stock, but it is very close to rallying. The results could give Novavax a boost and push the stock high.
Novavax Is a Buy on Recent Developments and Cheap Valuation
NVAX stock is one of the major players in the vaccine market, which is one that is expected to grow substantially over the next few years.
Production Updates Could Give Novavax Stock a Big Boost
Given the low expectations for Novavax's deliveries, better-than-expected numbers could send the NVAX stock price back to the triple digits.
Novavax Stock’s Wild Moves Leave Little Room for Error
NVAX stock can still bring profits for traders and investors as long as they are willing to accept the risks that it brings.
Why Novavax Has Limited Downside from Here
As countries potentially adopt a once yearly vaccination booster schedule for Covid-19, you can expect steady earnings for NVAX stock.
Dump Novavax Stock as Delays May Make Its Vaccine Practically Obsolete
Novavax's share price is down 41% year-to-date, bringing its six month decline to 63%, as the prospects of the biopharmaceutical company bringing a vaccine against Covid-19 to market grow dimmer by the hour.
Novavax Stock Is at Risk Despite Positive Poll Results
A recent poll supports Novavax's Covid treatment in the United States, but the vote on today's NVAX stock price chart warns against buying.
